Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Multiple lesions in receptor tyrosine kinase pathway determine glioblastoma response to pan-ERBB inhibitor PF-00299804 and PI3K/mTOR dual inhibitor PF-05212384.

Cancer biology & therapy - 1 Jun 2014

Zhu Yanni, Shah Khalid

Abstract excerpt

A novel pan ERBB inhibitor PF-00299804 (dacomitinib) is currently in phase II clinical trials in glioblastoma multiforme (GBM) patients; however its pre-clinical efficacy in GBMs has not been tested. In this study, we evaluated the efficacy of dacomitinib alone or in combination with PI3K/mTOR dual inhibitor PF-05212384 in GBM and assessed the mechanisms of resistance and the molecular determinants of response. A...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Screening Assays, Antitumor
Share to Drug Synergism

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glioblastoma

Share to Morpholines

Share to Phosphoinositide-3 Kinase Inhibitors

Share to Quinazolinones

Share to TOR Serine-Threonine Kinases

Share to Triazines

Source

Open in PubMed Open full text

Identifiers

PMID: 24658109
DOI: 10.4161/cbt.28585
PMCID: PMC4049797

Genes

EGFR
PTEN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Multiple lesions in receptor tyrosine kinase pathway determine glioblastoma response to pan-ERBB inhibitor PF-00299804 and PI3K/mTOR dual inhibitor PF-05212384.PMID 24658109Read ↗

Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.Semantic proximity Read ↗

A Potential Role for the Inhibition of PI3K Signaling in Glioblastoma TherapySemantic proximity Read ↗

TP53 mutated glioblastoma stem-like cell cultures are sensitive to dual mTORC1/2 inhibition while resistance in TP53 wild type cultures can be overcome by combined inhibition of mTORC1/2 and Bcl-2.Semantic proximity Read ↗

Combination MEK and mTOR inhibitor therapy is active in models of glioblastomaSemantic proximity Read ↗

Targeting the PI3K/AKT/mTOR and RAF/MEK/ERK pathways for cancer therapySemantic proximity Read ↗

Will kinase inhibitors make it as glioblastoma drugs?Semantic proximity Read ↗

Targeted therapy for malignant glioma patients: lessons learned and the road ahead.Semantic proximity Read ↗

Antitumor Activity of NVP-BKM120—A Selective Pan Class I PI3 Kinase Inhibitor Showed Differential Forms of Cell Death Based on p53 Status of Glioma CellsSemantic proximity Read ↗

Therapeutic targeting of EGFR-activated metabolic pathways in glioblastoma.Semantic proximity Read ↗

mTOR-Rictor-EGFR axis in oncogenesis and diagnosis of glioblastoma multiformeSemantic proximity Read ↗

Phase II trial of dacomitinib, a pan-human EGFR tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification.Semantic proximity Read ↗

Targeted Molecular Therapy of GBMSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.